Heme binds to factor VIII and inhibits its interaction with activated factor IX

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1062-1071

  Repesse Y ^a,b,c   Dimitrov, J D ^a,b,c   Peyron, I ^a,b,c   Moshai, E Farrokhi ^a,b,c   Kiger, L ^e   Dasgupta, S ^a,b,c   Delignat, S ^a,b,c,d   Marden, M C ^e   Kaveri, S V ^a,b,c,d   Lacroix Desmazes, S ^a,b,c,d  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Genetic Research Centre India   (India)

^e INSERM   (France)

Author keywords

Coagulation; Factor IX; Factor VIII; Heme; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; HEME; PROCOAGULANT; VON WILLEBRAND FACTOR;

ARTICLE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

BINDING SITES; BINDING, COMPETITIVE; BLOOD COAGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR IXA; FACTOR VIII; FACTOR VIIIA; HEME; HEMIN; HUMANS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; SURFACE PLASMON RESONANCE; VON WILLEBRAND FACTOR;

EID: 84861715437     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04724.x     Document Type: Article

References (37)

1. Munro A, Girvan H, McLean K, Cheesman M, Leys D. Heme and Hemoproteins. In: Warren M, Smith A, eds. Tetrapyrroles: Birth, Life and Death. New York, NY: Springer, 2009: 160-83.
2. Sassa S, Nagai T. The role of heme in gene expression. Int J Hematol 1996; 63: 167-78.
3. Ponka P. Cell biology of heme. Am J Med Sci 1999; 318: 241-56.
4. Wagener FA, Volk HD, Willis D, Abraham NG, Soares MP, Adema GJ, Figdor CG. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 2003; 55: 551-71.
5. Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett 2005; 157: 175-88.
6. Aft RL, Mueller GC. Hemin-mediated oxidative degradation of proteins. J Biol Chem 1984; 259: 301-5.
7. Grinshtein N, Bamm VV, Tsemakhovich VA, Shaklai N. Mechanism of low-density lipoprotein oxidation by hemoglobin-derived iron. Biochemistry 2003; 42: 6977-85.
8. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-54.
9. Watson CJ. Editorial: hematin and porphyria. N Engl J Med 1975; 293: 605-7.
10. Glueck R, Green D, Cohen I, Ts'ao CH. Hematin: unique effects of hemostasis. Blood 1983; 61: 243-9.
11. Volin L, Rasi V, Vahtera E, Tenhunen R. Heme arginate: effects on hemostasis. Blood 1988; 71: 625-8.
12. Green D, Furby FH, Berndt MC. The interaction of the factor VIII/von Willebrand factor complex with hematin. Thromb Haemost 1986; 56: 277-82.
13. Vehar GA, Keyt B, Eaton DH, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-42.
14. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
15. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999-2004.
16. Gilbert GE, Arena AA. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine. J Biol Chem 1995; 270: 18500-5.
17. Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994; 269: 7150-5.
18. Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost 1999; 82: 193-200.
19. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
20. Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112: 240-9.
21. Buchanan GR, Holtkamp CA. Reduced hemoglobin values in children and young adults with hemophilia. Pediatrics 1988; 81: 840-5.
22. Buchanan GR, Holtkamp CA, Johnson A. Reduced serum haptoglobin values in hemophiliacs receiving monoclonally purified factor VIII concentrates. Am J Hematol 1990; 33: 234-7.
23. Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, Jacquemin M, Saint-Remy JM, Bayry J, Kaveri SV, Lacroix-Desmazes S. Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Mol Immunol 2009; 47: 290-7.
24. Jacquemin MG, Desqueper BG, Benhida A, van der Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JG, Vermylen J, Saint-Remy JM. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
25. Turitto VT, Weiss HJ, Baumgartner HR. Decreased platelet adhesion on vessel segments in von Willebrand's disease: a defect in initial platelet attachment. J Lab Clin Med 1983; 102: 551-64.
26. Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 1990; 189: 229-34.
27. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001; 11: 343-51.
28. Fischer K, Pendu R, van Schooten CJ, van Dijk K, Denis CV, van den Berg HM, Lenting PJ. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009; 4: e6745.
29. Green D, Reynolds N, Klein J, Kohl H, Ts'ao CH. The inactivation of hemostatic factors by hematin. J Lab Clin Med 1983; 102: 361-9.
30. Nielsen VG, Cohen JB, Malayaman SN, Nowak M, Vosseller K. Fibrinogen is a heme-associated, carbon monoxide sensing molecule: a preliminary report. Blood Coagul Fibrinolysis 2011; 22: 443-7.
31. Nielsen VG, Arkebauer MR, Vosseller K. Redox-based thrombelastographic method to detect carboxyhemefibrinogen-mediated hypercoagulability. Blood Coagul Fibrinolysis 2012; 23: 104-7.
32. Beaven GH, Chen SH, d' Albis A, Gratzer WB. A spectroscopic study of the haemin - human-serum-albumin system. Eur J Biochem 1974; 41: 539-46.
33. Hrkal Z, Kalousek I, Vodrazka Z. Haeme binding to albumin and equilibria in the albumin-ferrihaemoglobin and albumin-haemopexin systems. Int J Biochem 1980; 12: 619-24.
34. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 1968; 32: 811-5.
35. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
36. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935-40.
37. Soeda T, Nogami K, Nishiya K, Takeyama M, Ogiwara K, Sakata Y, Yoshioka A, Shima M. The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor xase complex. J Biol Chem 2009; 284: 3379-88.